The fifth edition of the World Health Organization (WHO) classification of urogenital tumours
(WHO “Blue Book”), published in 2022, contains significant revisions. This review …

Abstract The Cancer Genome Atlas (TCGA) characterized the somatic genetic and genomic
alterations in renal cell carcinoma (RCC) encompassing the major RCC histological …

Renal cancer management is challenging from diagnosis to treatment and follow-up. In
cases of small renal masses and cystic lesions the differential diagnosis of benign or …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …

The 5th edition of the WHO Classification of Tumours of the Urinary and Male Genital
Systems contains relevant revisions and introduces a group of molecularly defined renal …

Background Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell
carcinomas, is a heterogeneous disease that consists of various types of renal cancer …

Human cancer genomes harbour a variety of alterations leading to the deregulation of key
pathways in tumour cells. The genomic characterization of tumours has uncovered …

The treatment of renal cell carcinoma (RCC) has changed greatly over the past 15 years.
Progress in the surgical management of the primary tumor and increased understanding of …

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …